ENGINEERS FAROUK AHMED, GBENGA KOMOLAFE RESIGN, PRESIDENT TINUBU NOMINATES SUCCESSORS TO THE SENATE FOR APPROVAL. (PHOTO). #PRESS RELEASE.

Image
 STATEHOUSE PRESS RELEASE   ENGINEERS FAROUK AHMED, GBENGA KOMOLAFE RESIGN, PRESIDENT TINUBU NOMINATES SUCCESSORS TO THE SENATE FOR APPROVAL President Bola Ahmed Tinubu has asked the Senate to approve the nominations of two new chief executives for the Nigerian Midstream and Downstream Petroleum Regulatory Authority (NMDPRA) and the Nigerian Upstream Petroleum Regulatory Commission (NUPRC).   The requests followed the resignation of Engineer Farouk Ahmed of the NMDPRA and Gbenga Komolafe of the NUPRC. Both officials were appointed in 2021 by former President Buhari to lead the two regulatory agencies created by the Petroleum Industry Act (PIA).   To fill these positions, President Tinubu has written to the Senate, requesting expedited confirmation of Oritsemeyiwa Amanorisewo Eyesan as CEO of NUPRC and Engineer Saidu Aliyu Mohammed as CEO of NMDPRA.   The two nominees are seasoned professionals in the oil and gas industry.   Eyesan, a graduate of Economics f...

CHINESE COVID-19 VACCINE SHOWS PROMISING RESULTS.[PHOTO}.

Chinese COVID-19 vaccine shows promising results - CGTN
   We are all expecting a COVID-19 vaccine that could possibly end the pandemic that has killed more than 330,000 people.
Now the first vaccine candidate from China has finished its phase-1 trial on humans, and the results have been put online for everyone to examine.
The Lancet, a respected medical journal in the UK, published the results on Friday saying it is "safe" and "induces rapid immune response."
The research injected the potential vaccine into 108 volunteers.
They were divided into three groups, each taking a different dose of the vaccine.
The vaccine, classified as "recombinant adenovirus type-5 vectored" (Ad5-nCoV), acts as a natural infection and is especially good at teaching the immune system how to fight the virus.During the next 28 days, no serious reactions were found, meaning the vaccine seemed to be tolerable by humans.Also, antibodies against the SARS-CoV-2 started to surge two weeks after the injection and reached its peak on day 28.The vaccine "warrants further investigation," the paper on The Lancet concluded.A phase-2 clinical trial has started with 508 volunteers involved.The trial was conducted by a team led by Chen Wei, a biology professor from Academy of Military Medical Sciences and a member of the Chinese Academy of Engineering.There are other two vaccines allowed for human trials in China. They are ShaCoVacc and PiCoVacc.-CCTV.
Chinese COVID-19 vaccine shows promising results - CGTN

Comments

Popular posts from this blog

SHAKIRA COVERS WOMEN'S HEALTH MAGAZINE,APRIL ISSUE.

INNOSON GIVES OUT BRAND NEW IVM G5 AND SALARY FOR LIFE TO THE MAN WHO PROPHESIED ABOUT HIS VEHICLE MANUFACTURING IN 1979.(PHOTO).

THE NEW OONI OF ILE-IFE,WILL NOT EAT THE HEART OF THE LATE OONI-PALACE CHIEFS.